Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

54
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
54
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

51
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
51
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

28
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
28
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 心筋線維症と心不全におけるアポトーシス関連非コーディングrna:病変発生と治療への影響

心筋線維症と心不全におけるアポトーシス関連非コーディングRNA:病変発生と治療への影響

Hao Wu1,2, Lei Xia1,2, Chunli Liu1,2

  • 1Shandong Public Health Clinical Center, Jinan, 250100, People's Republic of China.

Journal of inflammation research
|August 27, 2025

関連する実験動画

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.7K

PubMed で要約を見る

まとめ
この要約は機械生成です。

調節不良の非コーディングRNA (ncRNAs) は心筋細胞のアポトーシスを誘発し,心不全 (HF) と心筋線維症に寄与する. プロアポプトティックマイクロRNA (miRNA) の抑制は,これらの心血管疾患の有望な治療戦略を提供します.

科学分野:

  • 心血管生物学
  • 分子遺伝学
  • 細胞生物学

背景:

  • 心不全 (HF) と心臓線維症は 世界的に大きな健康問題です
  • アポトーシスはHFと心臓線維症の進行における重要なメカニズムです.
  • 非コーディングRNA (ncRNA) は遺伝子発現とアポトーシスを調節し,その不調は心血管疾患 (CVD) に寄与する.

研究 の 目的:

  • 心筋細胞のアポトーシスにおける ncRNA 失調の役割を調査する.
  • HFと心臓線維症のプロアポプトティックマイクロRNA (miRNA) を標的とした治療戦略を探求する.

主な方法:

  • ncRNA,アポトーシス,心血管疾患に関する現在の文献のレビュー.
  • ncRNAの調節不全と心筋細胞のアポトーシスを関連付けるメカニズムの分析
  • miRNAを標的とした治療方法の評価

主要な成果:

  • 過剰な心筋細胞のアポトーシスに関与している.
  • プロアポプトティックmiRNAsは,HFおよび心臓線維症の病原性において重要な役割を果たします.
  • 特定のmiRNAsの治療阻害は,これらの状態の治療の可能性を示しています.
キーワード:
アポトーシス心筋線維症心不全薬草

関連する実験動画

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.7K

結論:

  • ncRNAs,特にプロアポプトティックmiRNAsを標的にすることは,HFと心臓線維症の有望な治療法です.
  • 幹細胞由来エクソソームやハーブ医学のような戦略は,miRNAの活性を調節することで新しい治療法を提供することができます.
非コーディングRNA